XCNQ
CL
Market cap233mUSD
, Last price
CAD
Name
Cresco Labs Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Cresco Labs Inc. cultivates, manufactures, and sells retail and medical cannabis products in the United States and Germany. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes, gummies, and pre-rolls under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company offers cannabis flowers under the FloraCal brand; and cannabis oils and variety of bites are available at multiple potency levels under the Mindy’s brand, as well as Loud*r brand. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company is headquartered in Chicago, Illinois.
Key people
Non-Executive Chairman of the Board · since 2023
Gregory Butler
President · since 2024
Charles Bachtell
Chief Executive Officer, Director · since 2019
Sharon Schuler
Chief Financial Officer · since 2024
Angie Demchenko
Chief People Officer · since 2019
Zach Marburger
Chief Information Officer · since 2019
John Schetz
General Counsel · since 2018
Jason Erkes
Chief Communications Officer · since 2018
Gerald Corcoran
Independent Director · since 2018
Independent Director · since 2022
Randy Podolsky
Independent Director · since 2018
Michele Roberts
Independent Director · since 2020
Robert Sampson
Independent Director · since 2018
Legal address
25th Floor, 666 Burrard Street
Vancouver, BC V6C 2X8
CA
Vancouver, BC V6C 2X8
CA
Headquarters
400 West Erie Street, Suite 110
Chicago, IL 60654
US
Chicago, IL 60654
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2018‑01 | 2017‑01 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||